Clinical Trial

Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma

Name: Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma — clinical trial record (NCT07628595)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This is a single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of RN9101 injection for patients with relapsed/refractory multiple myeloma.

Trial Details

NCT Number	NCT07628595
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University
Conditions	Multiple Myeloma (MM)
Enrollment	19 participants
Start Date	2026-07-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-11-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-10